{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T05:01:36Z","timestamp":1789275696096,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.retram.2022.103360","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T07:31:16Z","timestamp":1659425476000},"page":"103360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0997-4293","authenticated-orcid":false,"given":"Junjie","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzhi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongzheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pisheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.retram.2022.103360_bib0001","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2162-3619-1-13","article-title":"Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011","volume":"1","author":"Ali","year":"2012","journal-title":"Exp Hematol Oncol"},{"issue":"23","key":"10.1016\/j.retram.2022.103360_bib0002","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1182\/blood-2011-11-389809","article-title":"The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission","volume":"119","author":"Huang","year":"2012","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.retram.2022.103360_bib0003","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.retram.2022.103360_bib0004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.exphem.2017.11.001","article-title":"T-cell-replete haploidentical transplantation in acute myeloid leukemia","volume":"58","author":"Castagna","year":"2018","journal-title":"Exp Hematol"},{"issue":"19","key":"10.1016\/j.retram.2022.103360_bib0005","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.retram.2022.103360_bib0006","first-page":"100235","article-title":"Fludarabine-based salvage therapy for refractory\/relapsed acute leukemias: a single center experience","volume":"15","author":"Abbasi","year":"2021","journal-title":"Leuk Res Rep"},{"issue":"4","key":"10.1016\/j.retram.2022.103360_bib0007","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.retram.2022.103360_bib0008","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/cncr.27761","article-title":"Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.retram.2022.103360_bib0009","unstructured":"Przepiorka D, Weisdorf DJ, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825\u2013828."},{"issue":"3","key":"10.1016\/j.retram.2022.103360_bib0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.retram.2022.103360_bib0011","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/bmt.2015.305","article-title":"Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission","volume":"51","author":"Ruggeri","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.retram.2022.103360_bib0012","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.retram.2022.103360_bib0013","doi-asserted-by":"crossref","first-page":"32579","DOI":"10.18632\/oncotarget.8691","article-title":"Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT","volume":"7","author":"Xuan","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.retram.2022.103360_bib0014","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/bmt.2016.15","article-title":"Long-term outcomes of allogeneic hematopoietic cell transplantation with intensified myeloablative conditioning for refractory myeloid malignancy","volume":"51","author":"Kawashima","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.retram.2022.103360_bib0015","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/bmt.2017.100","article-title":"Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia","volume":"52","author":"Zhang","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.retram.2022.103360_bib0016","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.mjt.0000181690.21601.09","article-title":"IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience","volume":"13","author":"Yavuz","year":"2006","journal-title":"Am J Ther"},{"issue":"1","key":"10.1016\/j.retram.2022.103360_bib0017","first-page":"46","article-title":"FLAG regimen with or without idarubicin in children with relapsed\/refractory acute leukemia: experience from a Turkish pediatric hematology center","volume":"34","author":"Bengoa","year":"2017","journal-title":"Turk J Haematol"},{"issue":"6","key":"10.1016\/j.retram.2022.103360_bib0018","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00280-019-03792-8","article-title":"FLAG vs FLAG-IDA: outcomes in relapsed\/refractory acute leukemias","volume":"83","author":"Farooq","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.retram.2022.103360_bib0019","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3892\/mco.2016.765","article-title":"Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patients","volume":"4","author":"Dai","year":"2016","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"10.1016\/j.retram.2022.103360_bib0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-019-0727-4","volume":"12","author":"Saraceni","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"15","key":"10.1016\/j.retram.2022.103360_bib0021","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","article-title":"Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial","volume":"16","author":"Rambaldi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.retram.2022.103360_bib0022","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcyt.2019.12.006","article-title":"Predicting in vitro human mesenchymal stromal cell expansion based on individual donor characteristics using machine learning","volume":"22","author":"Mehrian","year":"2020","journal-title":"Cytotherapy"},{"issue":"Suppl 2","key":"10.1016\/j.retram.2022.103360_bib0023","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1038\/bmt.2015.93","article-title":"Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update","volume":"50","author":"Bacigalupo","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.retram.2022.103360_bib0024","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.2016.151779","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant","volume":"102","author":"Ruggeri","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.retram.2022.103360_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.retram.2022.103360_bib0026","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00277-020-04033-2","article-title":"Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation","volume":"99","author":"Pasic","year":"2020","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.retram.2022.103360_bib0027","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000507536","article-title":"Post-transplant cyclophosphamide combined with anti-thymocyte globulin as graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplantation in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"144","author":"Alanazi","year":"2021","journal-title":"Acta Haematol"},{"issue":"7","key":"10.1016\/j.retram.2022.103360_bib0028","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.retram.2022.103360_bib0029","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1016\/j.bbmt.2020.08.010","article-title":"Does Post-Transplantation Cyclophosphamide Inhibit Graft-versus-Leukemia?","volume":"26","author":"Fuchs","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.retram.2022.103360_bib0030","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2020.06.026","article-title":"Timing of post-transplantation cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the acute leukemia working party of the european society for blood and marrow transplantation","volume":"26","author":"Ruggeri","year":"2020","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318622000289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318622000289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:41:15Z","timestamp":1762821675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318622000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2452318622000289"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2022.103360","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2022.103360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103360"}}